MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-29-2026
Pro-Dex Interest Expense 2011-2026 | PDEX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Pro-Dex
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 533 K | 464 K | 352 K | 236 K | 220 K | 7 K | 12 K | 37 K | 6 K | 8 K | 11 K | -36 K | -148 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 533 K | -148 K | 131 K |
Quarterly Interest Expense Pro-Dex
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 141 K | - | 246 K | 204 K | 152 K | - | 138 K | 139 K | 133 K | - | 131 K | 128 K | 130 K | 258 K | 112 K | 117 K | 120 K | 237 K | 102 K | 75 K | 54 K | 75 K | 54 K | 63 K | 59 K | 63 K | 59 K | 69 K | 20 K | 69 K | 20 K | 2 K | 2 K | 2 K | 2 K | 4 K | 3 K | 4 K | 3 K | 20 K | 6 K | 20 K | 6 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | - | 6 K | 6 K | 6 K | 10 K | 10 K | 9 K | 10 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 258 K | 2 K | 60.3 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
-16.4 M | $ 59.61 | -1.28 % | $ 11.9 B |  USA |
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 114.0 | -0.14 % | $ 3.65 B | USA |
 |
ICU Medical
ICUI
|
93.3 M | $ 118.72 | -3.47 % | $ 2.93 B | USA |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 3.9 | -2.01 % | $ 180 M | USA |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 97.31 | -2.2 % | $ 2.2 B | USA |
 |
Alcon
ALC
|
204 M | $ 63.64 | -0.56 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
300 K | $ 178.47 | 0.07 % | $ 9.51 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
-2.3 M | $ 23.22 | -2.68 % | $ 3.9 B | USA |
 |
electroCore
ECOR
|
14.9 K | $ 6.27 | -2.49 % | $ 53.2 K | USA |
 |
Haemonetics Corporation
HAE
|
-9.75 M | $ 56.29 | -1.4 % | $ 2.83 B | USA |
 |
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
13.6 M | $ 144.01 | 1.31 % | $ 6.97 B | USA |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 32.07 | 0.19 % | $ 1.59 B | USA |
 |
STERIS plc
STE
|
8.4 M | $ 212.11 | -1.79 % | $ 20.9 B | USA |
 |
Teleflex Incorporated
TFX
|
85.1 M | $ 129.71 | -0.44 % | $ 5.79 B | USA |
 |
InfuSystem Holdings
INFU
|
2 K | $ 8.77 | 1.86 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
-5 K | $ 1.85 | - | $ 84.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
60.3 K | $ 0.33 | -2.62 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 61.36 | -1.92 % | $ 3.63 B | USA |
 |
Utah Medical Products
UTMD
|
-120 K | $ 63.34 | -0.57 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
-1 M | $ 302.89 | 0.9 % | $ 21.9 B | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 24.55 | -9.41 % | $ 1.65 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
24 M | $ 10.08 | -3.17 % | $ 2.01 B | USA |
 |
Retractable Technologies
RVP
|
227 K | $ 0.64 | -7.25 % | $ 19.2 M | USA |
 |
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
1.82 M | $ 20.76 | -1.42 % | $ 991 M | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.85 | -4.64 % | $ 168 M | USA |
 |
Baxter International
BAX
|
290 M | $ 17.3 | -2.7 % | $ 8.87 B | USA |
 |
ResMed
RMD
|
3.2 M | $ 201.88 | -0.33 % | $ 29.5 B | USA |
 |
AtriCure
ATRC
|
683 K | $ 28.12 | -0.11 % | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.25 | -4.89 % | $ 233 M | USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 10.77 | -2.36 % | $ 440 M | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 143.47 | -0.73 % | $ 41.3 B | USA |
 |
Nephros
NEPH
|
-78 K | $ 3.13 | -6.29 % | $ 33.2 M | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 3.0 | 1.69 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
2.82 M | $ 102.87 | -0.49 % | $ 5.78 M | USA |